| 1. Ruenitz PC, Bagley JR, Mokler CM.. (1982) Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine., 25 (9): [PMID:7131484] [10.1021/jm00351a010] |
| 2. Gilbert J, Fuentes M, Ojasoo T, Doré JC, Pons M.. (1997) Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes., 40 (7): [PMID:9089332] [10.1021/jm950624t] |
| 3. Grese TA, Pennington LD, Sluka JP, Adrian MD, Cole HW, Fuson TR, Magee DE, Phillips DL, Rowley ER, Shetler PK, Short LL, Venugopalan M, Yang NN, Sato M, Glasebrook AL, Bryant HU.. (1998) Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators., 41 (8): [PMID:9548817] [10.1021/jm970688z] |
| 4. McCague R, Leclercq G, Jordan VC.. (1988) Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes., 31 (7): [PMID:3385723] [10.1021/jm00402a005] |
| 5. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, Muehl BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant HU.. (1997) Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator., 40 (10): [PMID:9154963] [10.1021/jm970167b] |
| 6. Schmidt JM, Mercure J, Tremblay GB, Pagé M, Kalbakji A, Feher M, Dunn-Dufault R, Peter MG, Redden PR.. (2003) De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor., 46 (8): [PMID:12672240] [10.1021/jm020536q] |
| 7. Ruenitz PC, Bagley JR, Nanavati NT.. (1988) Synthesis and estrogen receptor selectivity of 1,1-bis(4-hydroxyphenyl)-2-(p-halophenyl)ethylenes., 31 (7): [PMID:3385736] [10.1021/jm00402a037] |
| 8. Kim YW, Mobley JA, Brueggemeier RW.. (2003) Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain., 13 (8): [PMID:12668015] [10.1016/s0960-894x(03)00132-x] |
| 9. Lubczyk V, Bachmann H, Gust R.. (2003) Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity., 46 (8): [PMID:12672249] [10.1021/jm0210562] |
| 10. Foster AB, Jarman M, Leung OT, McCague R, Leclercq G, Devleeschouwer N.. (1985) Hydroxy derivatives of tamoxifen., 28 (10): [PMID:4045924] [10.1021/jm00148a020] |
| 11. Grese TA, Cho S, Finley DR, Godfrey AG, Jones CD, Lugar CW, Martin MJ, Matsumoto K, Pennington LD, Winter MA, Adrian MD, Cole HW, Magee DE, Phillips DL, Rowley ER, Short LL, Glasebrook AL, Bryant HU.. (1997) Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene., 40 (2): [PMID:9003514] [10.1021/jm9606352] |
| 12. Wallace OB, Lauwers KS, Jones SA, Dodge JA.. (2003) Tetrahydroquinoline-based selective estrogen receptor modulators (SERMs)., 13 (11): [PMID:12749895] [10.1016/s0960-894x(03)00306-8] |
| 13. Bignon E, Pons M, Crastes de Paulet AC, Doré JC, Gilbert J, Abecassis J, Miquel JF, Ojasoo T, Raynaud JP.. (1989) Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth., 32 (9): [PMID:2769681] [10.1021/jm00129a013] |
| 14. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F.. (1997) (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen., 40 (14): [PMID:9216828] [10.1021/jm970095o] |
| 15. Hardcastle IR, Rowlands MG, Houghton J, Parr IB, Potter GA, Jarman M, Edwards KJ, Laughton CA, Trent JO, Neidle S.. (1995) Rationally designed analogues of tamoxifen with improved calmodulin antagonism., 38 (2): [PMID:7830266] [10.1021/jm00002a005] |
| 16. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB.. (1989) Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent., 32 (12): [PMID:2585441] [10.1021/jm00132a006] |
| 17. Edwards KJ, Laughton CA, Neidle S.. (1992) A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin., 35 (15): [PMID:1322985] [10.1021/jm00093a006] |
| 18. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, Kallen J, Keller H, Schlaeppi JM, Stark W.. (2003) Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands., 46 (14): [PMID:12825935] [10.1021/jm030086h] |
| 19. McKie JA, Bhagwat SS, Brady H, Doubleday M, Gayo L, Hickman M, Jalluri RK, Khammungkhune S, Kois A, Mortensen D, Richard N, Sapienza J, Shevlin G, Stein B, Sutherland M.. (2004) Lead identification of a potent benzopyranone selective estrogen receptor modulator., 14 (13): [PMID:15177442] [10.1016/j.bmcl.2004.04.081] |
| 20. Doré JC, Gilbert J, Bignon E, Crastes de Paulet A, Ojasoo T, Pons M, Raynaud JP, Miquel JF.. (1992) Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation., 35 (3): [PMID:1738150] [10.1021/jm00081a021] |
| 21. Wallace OB, Bryant HU, Shetler PK, Adrian MD, Geiser AG.. (2004) Benzothiophene and naphthalene derived constrained SERMs., 14 (20): [PMID:15380208] [10.1016/j.bmcl.2004.07.072] |
| 22. Pigeon P, Top S, Vessières A, Huché M, Hillard EA, Salomon E, Jaouen G.. (2005) Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior., 48 (8): [PMID:15828819] [10.1021/jm049268h] |
| 23. Zuercher WJ, Gaillard S, Orband-Miller LA, Chao EY, Shearer BG, Jones DG, Miller AB, Collins JL, McDonnell DP, Willson TM.. (2005) Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma., 48 (9): [PMID:15857113] [10.1021/jm050161j] |
| 24. Hoekstra WJ, Patel HS, Liang X, Blanc JB, Heyer DO, Willson TM, Iannone MA, Kadwell SH, Miller LA, Pearce KH, Simmons CA, Shearin J.. (2005) Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling., 48 (6): [PMID:15771467] [10.1021/jm040154f] |
| 25. Lill MA, Winiger F, Vedani A, Ernst B.. (2005) Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals., 48 (18): [PMID:16134935] [10.1021/jm050403f] |
| 26. Clegg NJ, Paruthiyil S, Leitman DC, Scanlan TS.. (2005) Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands., 48 (19): [PMID:16162002] [10.1021/jm050226i] |
| 27. Chao EY, Collins JL, Gaillard S, Miller AB, Wang L, Orband-Miller LA, Nolte RT, McDonnell DP, Willson TM, Zuercher WJ.. (2006) Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma., 16 (4): [PMID:16307879] [10.1016/j.bmcl.2005.11.030] |
| 28. Ito C, Itoigawa M, Kumagaya M, Okamoto Y, Ueda K, Nishihara T, Kojima N, Furukawa H.. (2006) Isoflavonoids with antiestrogenic activity from Millettia pachycarpa., 69 (1): [PMID:16441086] [10.1021/np050341w] |
| 29. Gao M, Wang M, Miller KD, Sledge GW, Zheng QH.. (2008) Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer., 43 (10): [PMID:18272256] [10.1016/j.ejmech.2008.01.001] |
| 30. Barrett I, Meegan MJ, Hughes RB, Carr M, Knox AJ, Artemenko N, Golfis G, Zisterer DM, Lloyd DG.. (2008) Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators., 16 (21): [PMID:18835176] [10.1016/j.bmc.2008.09.035] |
| 31. Bellavance E, Luu-The V, Poirier D.. (2009) Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone., 52 (23): [PMID:19772289] [10.1021/jm900921c] |
| 32. Maximov PY, Myers CB, Curpan RF, Lewis-Wambi JS, Jordan VC.. (2010) Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen., 53 (8): [PMID:20334368] [10.1021/jm901907u] |
| 33. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA.. (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness., 5 (2): [PMID:19136975] [10.1038/nchembio.140] |
| 34. Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, Wang G.. (2010) Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells., 53 (16): [PMID:20669983] [10.1021/jm100610w] |
| 35. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER.. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30., 2 (4): [PMID:16520733] [10.1038/nchembio775] |
| 36. Dettmann S, Szymanowitz K, Wellner A, Schiedel A, Müller CE, Gust R.. (2010) 2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation., 18 (14): [PMID:20598555] [10.1016/j.bmc.2010.06.016] |
| 37. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 38. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 39. Khupse RS, Sarver JG, Trendel JA, Bearss NR, Reese MD, Wiese TE, Boue SM, Burow ME, Cleveland TE, Bhatnagar D, Erhardt PW.. (2011) Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I., 54 (10): [PMID:21513275] [10.1021/jm101619e] |
| 40. Bourassa P, Dubeau S, Maharvi GM, Fauq AH, Thomas TJ, Tajmir-Riahi HA.. (2011) Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin., 46 (9): [PMID:21777996] [10.1016/j.ejmech.2011.07.005] |
| 41. Tukey RH, Strassburg CP.. (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease., 40 (1): [PMID:10836148] [10.1146/annurev.pharmtox.40.1.581] |
| 42. Dadiboyena S.. (2012) Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator., 51 [PMID:22405286] [10.1016/j.ejmech.2012.02.021] |
| 43. Chalmers MJ, Wang Y, Novick S, Sato M, Bryant HU, Montrose-Rafizdeh C, Griffin PR, Dodge JA.. (2012) Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs., 3 (3): [PMID:22582136] [10.1021/ml2002532] |
| 44. Jiang Q, Zhong Q, Zhang Q, Zheng S, Wang G.. (2012) Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer., 3 (5): [PMID:23864928] [10.1021/ml3000287] |
| 45. Rao US, Fine RL, Scarborough GA.. (1994) Antiestrogens and steroid hormones: substrates of the human P-glycoprotein., 48 (1): [PMID:7914405] [10.1016/0006-2952(94)90099-x] |
| 46. Bekaii-Saab TS, Perloff MD, Weemhoff JL, Greenblatt DJ, von Moltke LL.. (2004) Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A., 25 (1): [PMID:15386482] [10.1002/bdd.411] |
| 47. PubChem BioAssay data set, |
| 48. Weiser PT, Williams AB, Chang CY, McDonnell DP, Hanson RN.. (2012) 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding., 22 (21): [PMID:23017882] [10.1016/j.bmcl.2012.09.007] |
| 49. Ellis GA, McGrath NA, Palte MJ, Raines RT.. (2012) Ribonuclease-Activated Cancer Prodrug., 3 (4): [PMID:22611478] [10.1021/ml2002554] |
| 50. Lv W, Liu J, Lu D, Flockhart DA, Cushman M.. (2013) Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities., 56 (11): [PMID:23731360] [10.1021/jm400364h] |
| 51. Christodoulou MS, Fokialakis N, Passarella D, García-Argáez AN, Gia OM, Pongratz I, Dalla Via L, Haroutounian SA.. (2013) Synthesis and biological evaluation of novel tamoxifen analogues., 21 (14): [PMID:23735829] [10.1016/j.bmc.2013.05.012] |
| 52. Dwivedi SK, Samanta K, Yadav M, Jana AK, Singh AK, Chakravarti B, Mondal S, Konwar R, Trivedi AK, Chattopadhyay N, Sanyal S, Panda G.. (2013) Amino acids derived benzoxazepines: design, synthesis and antitumor activity., 23 (24): [PMID:24189055] [10.1016/j.bmcl.2013.10.013] |
| 53. Shoda T, Okuhira K, Kato M, Demizu Y, Inoue H, Naito M, Kurihara M.. (2014) Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator., 24 (1): [PMID:24332630] [10.1016/j.bmcl.2013.11.078] |
| 54. PubChem BioAssay data set, |
| 55. Bandyopadhyay D, Rivera G, Sanchez JL, Rivera J, Granados JC, Guerrero AM, Chang FM, Dearth RK, Short JD, Banik BK.. (2014) Bismuth nitrate-induced novel nitration of estradiol: an entry to new anticancer agents., 82 [PMID:24946145] [10.1016/j.ejmech.2014.06.010] |
| 56. Maximov PY, Fernandes DJ, McDaniel RE, Myers CB, Curpan RF, Jordan VC.. (2014) Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells., 57 (11): [PMID:24805199] [10.1021/jm500569h] |
| 57. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 58. Gege C, Schlüter T, Hoffmann T.. (2014) Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt., 24 (22): [PMID:25305688] [10.1016/j.bmcl.2014.09.053] |
| 59. Ohta K, Chiba Y, Kaise A, Endo Y.. (2015) Structure-activity relationship study of diphenylamine-based estrogen receptor (ER) antagonists., 23 (4): [PMID:25614118] [10.1016/j.bmc.2014.12.022] |
| 60. Kumar A, Gupta G, Bishnoi AK, Saxena R, Saini KS, Konwar R, Kumar S, Dwivedi A.. (2015) Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents., 23 (4): [PMID:25618595] [10.1016/j.bmc.2014.12.037] |
| 61. Sridar C, D'Agostino J, Hollenberg PF.. (2012) Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein., 40 (12): [PMID:22942317] [10.1124/dmd.112.047266] |
| 62. Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, Douglas K, Sensintaffar J, Lu N, Lee KJ, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, Moon MJ, Joseph JD, Darimont B, Brigham D, Grillot K, Heyman R, Rix PJ, Hager JH, Smith ND.. (2015) Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts., 58 (12): [PMID:25879485] [10.1021/acs.jmedchem.5b00054] |
| 63. Shoda T, Kato M, Harada R, Fujisato T, Okuhira K, Demizu Y, Inoue H, Naito M, Kurihara M.. (2015) Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators., 23 (13): [PMID:26003343] [10.1016/j.bmc.2015.05.002] |
| 64. Tang C, Li C, Zhang S, Hu Z, Wu J, Dong C, Huang J, Zhou HB.. (2015) Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer., 58 (11): [PMID:25993269] [10.1021/acs.jmedchem.5b00099] |
| 65. De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, Andrews DM, Ballard P, Buttar D, Callis RJ, Currie GS, Curwen JO, Davies CD, Donald CS, Feron LJ, Gingell H, Glossop SC, Hayter BR, Hussain S, Karoutchi G, Lamont SG, MacFaul P, Moss TA, Pearson SE, Tonge M, Walker GE, Weir HM, Wilson Z.. (2015) Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist., 58 (20): [PMID:26407012] [10.1021/acs.jmedchem.5b00984] |
| 66. Ahmed NS, Elghazawy NH, ElHady AK, Engel M, Hartmann RW, Abadi AH.. (2016) Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism., 112 [PMID:26896706] [10.1016/j.ejmech.2016.02.026] |
| 67. Yu DD, Huss JM, Li H, Forman BM.. (2017) Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ., 25 (5): [PMID:28189393] [10.1016/j.bmc.2017.01.019] |
| 68. Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F, Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C, Sun Y, Thomsen NM, Wang C, Wang J, Peukert S.. (2017) Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer., 60 (7): [PMID:28296398] [10.1021/acs.jmedchem.6b01468] |
| 69. Misawa T, Tanaka K, Demizu Y, Kurihara M.. (2017) Efficient synthesis of a multi-substituted diphenylmethane skeleton as a steroid mimetic., 27 (11): [PMID:28400239] [10.1016/j.bmcl.2017.03.066] |
| 70. Yang L, Hu Z, Luo J, Tang C, Zhang S, Ning W, Dong C, Huang J, Liu X, Zhou HB.. (2017) Dual functional small molecule fluorescent probes for image-guided estrogen receptor-specific targeting coupled potent antiproliferative potency for breast cancer therapy., 25 (13): [PMID:28506582] [10.1016/j.bmc.2017.05.002] |
| 71. Capuzzi SJ, Sun W, Muratov EN, Martínez-Romero C, He S, Zhu W, Li H, Tawa G, Fisher EG, Xu M, Shinn P, Qiu X, García-Sastre A, Zheng W, Tropsha A.. (2018) Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors., 61 (8): [PMID:29624387] [10.1021/acs.jmedchem.8b00035] |
| 72. Patch RJ, Huang H, Patel S, Cheung W, Xu G, Zhao BP, Beauchamp DA, Rentzeperis D, Geisler JG, Askari HB, Liu J, Kasturi J, Towers M, Gaul MD, Player MR.. (2017) Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents., 138 [PMID:28735214] [10.1016/j.ejmech.2017.07.015] |
| 73. Nagasawa J, Govek S, Kahraman M, Lai A, Bonnefous C, Douglas K, Sensintaffar J, Lu N, Lee K, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, Joseph JD, Darimont B, Brigham D, Maheu K, Heyman R, Rix PJ, Hager JH, Smith ND.. (2018) Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer., 61 (17): [PMID:30086626] [10.1021/acs.jmedchem.8b00921] |
| 74. O'Boyle NM, Barrett I, Greene LM, Carr M, Fayne D, Twamley B, Knox AJS, Keely NO, Zisterer DM, Meegan MJ.. (2018) Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity., 61 (2): [PMID:28426931] [10.1021/acs.jmedchem.6b01917] |
| 75. Palermo AF, Diennet M, El Ezzy M, Williams BM, Cotnoir-White D, Mader S, Gleason JL.. (2018) Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm., 26 (15): [PMID:30078609] [10.1016/j.bmc.2018.07.026] |
| 76. Luo J, Hu Z, Xiao Y, Yang T, Dong C, Huang J, Zhou HB.. (2017) Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy., 8 (7): [PMID:30108860] [10.1039/C7MD00163K] |
